Throughout the last three months, 12 analysts have evaluated Jazz Pharmaceuticals (NASDAQ:JAZZ), offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $166.92, a high estimate of $210.00, and a low estimate of $113.00. A 3.36% drop is evident in the current average compared to the previous average price target…